Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07384936 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Topefilgrastim Injection in the Treatment of High-Risk Pregnant Patients With Preeclampsia

StatusNot Yet Recruiting
PhaseNot applicable
SponsorFang Wang
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Fang Wang
2 trials monitored
See all monitored trials
This study is an open-label, prospective investigation designed to enroll 100 high-risk pregnant subjects with preeclampsia (PE). Participants will be allocated in a 2:2:1 ratio to one of three groups: the Topefilgrastim 0.5mg/biweekly group, the Topefilgrastim 1mg/biweekly group, or the control group, based on investigator judgment and patient preference. The overall study consists of three parts: a screening period, a treatment period, and a follow-up period.
Trial Details
NCT Number NCT07384936
Lead Sponsor Fang Wang
Collaborators: Xiamen Amoytop Biotech Co., Ltd.
Conditions
(from sponsor)		 Preeclampsia
Related terms Pre-Eclampsia
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov